NASDAQ:OBSV - Obseva Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$12.38 -0.53 (-4.11 %)
(As of 11/20/2018 06:25 AM ET)
Previous Close$12.91
Today's Range$11.70 - $12.92
52-Week Range$9.05 - $20.35
Volume54,800 shs
Average Volume129,515 shs
Market Capitalization$470.39 million
P/E RatioN/A
Dividend YieldN/A
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age. The company was founded in 2012 and is headquartered in Plan-les-Ouates, Switzerland.

Receive OBSV News and Ratings via Email

Sign-up to receive the latest news and ratings for OBSV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Current SymbolNASDAQ:OBSV
Previous Symbol


Debt-to-Equity RatioN/A
Current Ratio12.13
Quick Ratio12.13


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.30 per share
Price / Book3.75


EPS (Most Recent Fiscal Year)($2.25)
Net Income$-66,920,000.00
Net MarginsN/A
Return on Equity-51.74%
Return on Assets-46.92%


Outstanding Shares36,440,000
Market Cap$470.39 million
OptionableNot Optionable

Obseva (NASDAQ:OBSV) Frequently Asked Questions

What is Obseva's stock symbol?

Obseva trades on the NASDAQ under the ticker symbol "OBSV."

How were Obseva's earnings last quarter?

Obseva SA (NASDAQ:OBSV) released its quarterly earnings results on Thursday, November, 8th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.04. View Obseva's Earnings History.

When is Obseva's next earnings date?

Obseva is scheduled to release their next quarterly earnings announcement on Friday, March 8th 2019. View Earnings Estimates for Obseva.

What price target have analysts set for OBSV?

6 equities research analysts have issued 12-month price targets for Obseva's shares. Their forecasts range from $24.00 to $44.00. On average, they anticipate Obseva's share price to reach $31.1667 in the next twelve months. This suggests a possible upside of 151.8% from the stock's current price. View Analyst Price Targets for Obseva.

What is the consensus analysts' recommendation for Obseva?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obseva in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Obseva.

What are Wall Street analysts saying about Obseva stock?

Here are some recent quotes from research analysts about Obseva stock:
  • 1. According to Zacks Investment Research, "ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman's reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. " (10/18/2018)
  • 2. HC Wainwright analysts commented, "We anticipate top-line data within the next few weeks from the Phase 2b EDELWEISS trial of OBE2109 (linzagolix), ObsEva’s main clinical-stage asset, in women with endometriosis. As a reminder, the broad goal of this study is the identification of two distinct therapeutic dosing options to serve the needs of the large and diverse endometriosis patient population: (1) a dosage with the potential for alleviating patient symptoms with moderate estrogen suppression that does not meaningfully decrease bone mineral density (BMD), thus obviating the need for hormonal add- back therapy (ABT); and (2), a higher dosage that fully or nearly fully suppresses estrogen, which would require ABT to restore estrogen with the purpose of counteracting bone loss." (6/11/2018)

Has Obseva been receiving favorable news coverage?

Media coverage about OBSV stock has been trending somewhat positive this week, according to InfoTrie. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Obseva earned a news sentiment score of 1.2 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future.

Who are some of Obseva's key competitors?

Who are Obseva's key executives?

Obseva's management team includes the folowing people:
  • Dr. Ernest Loumaye, Co-Founder, CEO & Director (Age 66)
  • Mr. Timothy M. Adams, Chief Financial Officer (Age 58)
  • Dr. Jean-Pierre Gotteland Ph.D., Chief Scientific Officer (Age 53)
  • Mr. Mario Vincent Corso, Sr. Director of Investor Relations
  • Dr. Elke Bestel, Chief Medical Officer & Head of Pharmacovigilance (Age 52)

When did Obseva IPO?

(OBSV) raised $98 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 6,500,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.

Who are Obseva's major shareholders?

Obseva's stock is owned by many different of institutional and retail investors. Top institutional investors include First Manhattan Co. (4.21%), FMR LLC (3.92%), VHCP Management III LLC (3.18%), Vivo Capital LLC (2.57%), Credit Suisse AG (0.79%) and Point72 Asset Management L.P. (0.48%).

Which major investors are selling Obseva stock?

OBSV stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Laurion Capital Management LP and Point72 Asset Management L.P..

Which major investors are buying Obseva stock?

OBSV stock was acquired by a variety of institutional investors in the last quarter, including VHCP Management III LLC, Credit Suisse AG, Renaissance Technologies LLC, Zurcher Kantonalbank Zurich Cantonalbank , Citadel Advisors LLC, GSA Capital Partners LLP, First Manhattan Co. and Dimensional Fund Advisors LP.

How do I buy shares of Obseva?

Shares of OBSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Obseva's stock price today?

One share of OBSV stock can currently be purchased for approximately $12.38.

How big of a company is Obseva?

Obseva has a market capitalization of $470.39 million. The company earns $-66,920,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis. Obseva employs 39 workers across the globe.

What is Obseva's official website?

The official website for Obseva is

How can I contact Obseva?

Obseva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The company can be reached via phone at 41-22-552-3840 or via email at [email protected]

MarketBeat Community Rating for Obseva (NASDAQ OBSV)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  168 (Vote Outperform)
Underperform Votes:  152 (Vote Underperform)
Total Votes:  320
MarketBeat's community ratings are surveys of what our community members think about Obseva and other stocks. Vote "Outperform" if you believe OBSV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OBSV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel